
COGT Stock Forecast & Price Target
COGT Analyst Ratings
Bulls say
Cogent Biosciences Inc. is positioned for significant growth, with 2025 anticipated as a pivotal year that may enhance its attractiveness for mergers and acquisitions, particularly influenced by the outcomes of the APEX and PEAK trials. The company has markedly increased its probability of approval for its therapy bezuclastinib when combined with Sutent in second-line gastrointestinal stromal tumors, now estimated at 90%, alongside an upgraded peak penetration rate to 35%. The encouraging results from the APEX, PEAK, and SUMMIT trials suggest that bezuclastinib could establish itself as a competitive treatment across various malignancies, supporting a strong outlook for Cogent's financial performance.
Bears say
Cogent Biosciences is projecting a significant net loss of $2.28 per share for the full year of 2025, indicating persistent financial challenges. The company faces numerous risks, including negative clinical data for key therapies, slower development timelines, and potential regulatory setbacks, all of which could hinder its ability to achieve commercial success. Additionally, concerns regarding long-term dilution risk further contribute to a negative outlook on the company’s financial stability.
This aggregate rating is based on analysts' research of Cogent Biosciences, Inc. and is not a guaranteed prediction by Public.com or investment advice.
COGT Analyst Forecast & Price Prediction
Start investing in COGT
Order type
Buy in
Order amount
Est. shares
0 shares